In this retrospective cohort study, we compared clinical outcomes in the I-SPY 2 trial across patient racial groups among women with clinically (ERBB2-positive or HR-negative) or genomically (based on MammaPrint molecular subtyping) high-risk breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.